Article
Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.
ESMO open - 1 Nov 2020
Boilève Alice, Dufresne Armelle, Chamseddine Ali, Nassif Elise, Dumont Sarah, Brahmi Medhi, Adam Julien, Rouleau Etienne, Karanian Marie, Haddad Véronique, Faron Matthieu, Honoré Charles, Meeus Pierre, Le Cesne Axel, Blay Jean-Yves, Mir Olivier
Abstract excerpt
BACKGROUND: Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II/III studies. This might theoretically result either in increased survival or in early emergence of resistance to approved MKIs. METHODS: To assess whether using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.